|March 21, 2012|
|13:13 EDT||MYGN||Myriad Genetics has little risk from Prometheus ruling, says Cowen|
Cowen said patent consultants see little risk to Myriad from the Prometheus Supreme Court decision ruling. Shares are Neutral rated.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
|March 4, 2014|
|07:14 EDT||MYGN||NCCN updates guidelines for hereditary colon cancer testing |
Myriad Genetics is pleased to note that the National Comprehensive Cancer Network, or NCCN, has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults. Myriad believes the new guidelines will dramatically expand the number of patients eligible for hereditary colon cancer testing, especially among at-risk asymptomatic patients for whom screening has historically been limited based upon prior guidelines and a lack of insurance reimbursement. Some of the key aspects of the new guidelines include: A recommendation that all patients who meet a five percent or greater risk threshold for Lynch syndrome are appropriate for testing; a recommendation against sequential testing for the five Lynch syndrome genes in lieu of panel testing; an acknowledgement that patients with cancer can proceed directly to sequencing tests without a complicated tissue screening algorithm.
|March 3, 2014|
|07:19 EDT||MYGN||Myriad Genetics publishes clinical study for Prolaris |
Myriad Genetics announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients.
|February 25, 2014|
|07:16 EDT||MYGN||Myriad Genetics firing on all cylinders, says Cantor|
After meeting with Myriad's management, Cantor thinks that the company could have significant opportunities from the diversification of its PROLARIS and Crescendo products in the near to medium term. The firm raised its price target on the stock to $42 from $39 and reiterates a Buy rating on the shares.
|February 24, 2014|
|09:37 EDT||MYGN||Myriad Genetics price target increased to $48 from $39 at Stephens|
Stephens said a recent meeting with Myriad Genetics' management makes the firm more bullish on the near-term and long-term prospects for the company. The firm raised its price target on the stock to $48 and reiterates its Overweight rating on the shares.